期刊文献+

培美曲塞及吉西他滨联合铂类一线治疗有吸烟史的晚期非小细胞肺癌患者的疗效观察 被引量:2

下载PDF
导出
摘要 目的:比较培美曲塞及吉西他滨联合铂类一线治疗有吸烟史的晚期非小细胞肺癌的疗效。方法:回顾性分析2009年1月至2010年12月在广西医科大学附属肿瘤医院化疗科接受培美曲塞联合铂类及吉西他滨联合铂类一线化疗的有吸烟病史的83例晚期非小细胞肺癌患者,分别比较两组患者的客观缓解率、疾病控制率、无进展生存时间和总生存时间。结果:42例患者接受培美曲塞联合铂类化疗,41例患者接受吉西他滨联合铂类化疗。培美曲塞组与吉西他滨组的客观缓解率为19%和34.1%,差异无统计学意义(P=0.119),疾病控制率分别为59.5%和80.5%,中位无进展生存(mPFS)为4.8和5.6个月,差异有统计学意义(P=0.037,P=0.02),中位总生存(mOS)为11.0个月和12.3个月,差异无统计学意义(P=0.443)。结论:对有吸烟史的晚期非小细胞肺癌患者进行一线化疗,吉西他滨联合铂类方案的疗效可能优于培美曲塞联合铂类方案。
出处 《广西医科大学学报》 CAS 2014年第4期601-603,共3页 Journal of Guangxi Medical University
  • 相关文献

参考文献10

  • 1Scagliotti GV, Parikh P, von Pawel J, et al. Phase I]I study comparing cisplatin plus gemcitabine with cispla- tin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J]. J Clin Onco,2008,26:3 543-3 551.
  • 2Scagliotti GV, Hanna N, Fossella F, et al. The differ- ential efficacy of pemetrexed accordino to NSCLC his- tology: a review of two phase III studies[J]. Oncolo- gist, 2009,14 : 253-263.
  • 3Frances A. Shepherd,Janet Dancey, Andrem Arnold, et al. Phase ]] Study of Pemetrezed Disodium,a Multitar- geted Antifotate and Cisplatin as First-Line Therapy in Patients with Advanced Nonsmall Cell Lung Carcinoma [J]. Cancer,2001,92(3) : 595-600.
  • 4Yang CH,Simms L,Park K, et al. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian paitients with ad- vanced non-small cell lung cancer: results of an explora- tory subgroup analysis of phase II trial[J]. J Thorae Oncol, 2010,5 : 688-695.
  • 5Sun JM, Han J, Ahn JS, et al. Significance of thymidy- late synthase and thyroid transcription factor 1 expres- sion in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy [J].J Thorae Oncol, 2011,6:1 392-1 399.
  • 6Chen CY, Chang YL, Shih JY, et al. Thymidylate syn- thase and dihydrofolate reductase expression in non- small cell lung carcinoma., the association with treat- ment efficacy of pemetrexed[J]. Lung Cancer, 2011, 74 : 132-138.
  • 7Takezawa K, Okamoto I, Okamoto W,et al. Thymidy- late synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer[J]. Br J Cancer, 2011, 104:1 594 1 601.
  • 8Nicolson, Marianne C, Fennell, et al. Thymidylate Syn- thase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non-Small- Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial[J]. Journal of Thoracic Oncolo- gy,2013,8(7) :930-939.
  • 9Shaw AT, Varghese AM, Solomon BJ, et al. Peme- trexed-based chemotherapy in patients with advanced, ALK-positive non-small ceil lung cancer[J]. Ann On- col,2013,24(1) :59-66.
  • 10Chang MH, Ahn JS, Lee J,et al. The efficacy of peme- trexed as a third- or fourth line therapy and the signifi- cance of thymidylate synthase expression in patients with advanced non-small cell lung cancer [J]. Lung Cancer, 2010,69 (3): 323-329.

同被引文献12

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部